Torray Investment Partners LLC Decreases Stake in Amgen Inc. $AMGN

Torray Investment Partners LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,647 shares of the medical research company’s stock after selling 7,883 shares during the quarter. Amgen accounts for about 3.0% of Torray Investment Partners LLC’s investment portfolio, making the stock its 11th biggest holding. Torray Investment Partners LLC’s holdings in Amgen were worth $21,160,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. West Family Investments Inc. raised its stake in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares during the last quarter. Viawealth LLC raised its stake in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after purchasing an additional 30 shares during the last quarter. LOM Asset Management Ltd raised its stake in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after purchasing an additional 30 shares during the last quarter. Smith Salley Wealth Management raised its stake in shares of Amgen by 0.3% in the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock worth $3,530,000 after purchasing an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC increased its position in Amgen by 4.0% during the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Guggenheim nudged its price target higher to $351 from $347, citing an updated model ahead of Amgen’s upcoming earnings — a modest validation of valuation that can support the stock. Read More.
• Neutral Sentiment: Amgen announced the retirement of David M. Reese, EVP and Chief Technology Officer, effective June 30; the company describes a leadership realignment to emphasize integration of biology and technology — a governance change to watch for execution risk but not an immediate earnings driver. Read More.
• Neutral Sentiment: Canaccord Genuity initiated coverage with a Hold and Bernstein reiterated/issued a Hold — multiple hold ratings may cap near-term upside as analysts await clearer catalysts. Read More.
• Neutral Sentiment: Media pieces (e.g., Zacks) flag AMGN as a trending stock, raising retail attention but not adding new fundamental information. Read More.
• Negative Sentiment: Company insiders sold about US$4.1M of Amgen stock over the past year — insider selling can be interpreted as a sign of caution and may weigh on investor sentiment even if sales have various benign explanations. Read More.

Amgen Stock Performance

NASDAQ:AMGN traded up $3.13 during mid-day trading on Thursday, hitting $349.05. 166,376 shares of the company traded hands, compared to its average volume of 2,711,417. The firm has a market cap of $188.38 billion, a price-to-earnings ratio of 24.53, a price-to-earnings-growth ratio of 3.61 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s fifty day moving average price is $361.59 and its 200-day moving average price is $338.73. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the company earned $5.31 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 22.18 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research report on Wednesday, April 8th. Jefferies Financial Group initiated coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Deutsche Bank Aktiengesellschaft upped their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Finally, Daiwa Securities Group upped their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.